Animal studies have shown no selective reproductive toxicity (see Pharmacology: Toxicology: Preclinical Safety Data under Actions). There are no adequate or well-controlled data regarding the use of anidulafungin in pregnant women. Therefore, anidulafungin should only be used during pregnancy if the potential benefit to the mother outweighs the potential risk to the fetus.
Animal studies have shown excretion of anidulafungin in breast milk. It is not known whether anidulafungin is excreted in human breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with anidulafungin should be made taking into account the benefit of breast-feeding to the child and the benefit of anidulafungin to the mother.